Pentamethylquercetin (PMQ) reduces thrombus formation by inhibiting platelet function

Area of Science:

• Pharmacology
• Biochemistry
• Cardiovascular Research

Background:

• Flavonoids are known for antioxidant and anti-platelet properties.
• Pentamethylquercetin (PMQ), a polymethoxylated flavone, has shown anti-carcinogenic and cardioprotective effects.
• The anti-thrombotic potential of PMQ remains largely unexplored.

Purpose of the Study:

• To investigate the anti-thrombotic activity of Pentamethylquercetin (PMQ).
• To elucidate the in vitro mechanisms underlying PMQ's effects on platelet function.
• To assess PMQ's therapeutic potential in thrombotic disorders.

Main Methods:

• PMQ's efficacy was tested in vivo using collagen-epinephrine-induced pulmonary thrombosis and ferric chloride-induced carotid injury mouse models.
• In vitro studies evaluated PMQ's impact on platelet aggregation and granule secretion induced by various agonists (ADP, collagen, thrombin, U46619).
• Biochemical analyses assessed the activation of key signaling molecules (Syk, PLCγ2, Akt, GSK3β, Erk1/2) following PMQ treatment.

Main Results:

• PMQ (20 mg/kg) significantly inhibited thrombus formation in both pulmonary and carotid injury models.
• PMQ suppressed platelet aggregation and granule secretion induced by low-dose agonists.
• PMQ effectively inhibited the activation of Syk, PLCγ2, Akt, GSK3β, and Erk1/2 signaling pathways.

Conclusions:

• This study provides the first evidence of Pentamethylquercetin's (PMQ) anti-thrombotic activity in vivo.
• PMQ demonstrates potent inhibition of platelet function in vitro.
• PMQ emerges as a promising therapeutic candidate for managing thrombotic disorders.